Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 10Thoracic 2Dermatologic 2Breast 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 11Neoplasms 3Neoplasm Metastasis 3Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Sezary Syndrome 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Pharyngeal Neoplasms 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1

Interventions

pembrolizumab 9Cyclophosphamide 6fludarabine phosphate 4aldesleukin 3Radiotherapy 3Gemcitabine 3Drug Therapy 3Docetaxel 3Cetuximab 3temsirolimus 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2fludarabine 2entinostat 2durvalumab 2belinostat 2atezolizumab 2Sirolimus 2Paclitaxel 2Methods 2Metformin 2Irinotecan 2Interferon-alpha 2Bortezomib 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1tremelimumab 1tocilizumab 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × temsirolimus × Breast × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00659568 2013-05-30

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
28 enrolled
BreastDermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmThoracic

Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Renal Cell, Hodgkin Disease, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Endometrial Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡